Navigation Links
B. Braun Renal Therapies Division Announces Availability of Adimea

BETHLEHEM, Pa., April 27 /PRNewswire/ -- The Renal Therapies Division of B. Braun Medical Inc. (B. Braun) has announced the U.S. introduction of Adimea™, an innovative process for real-time monitoring of dialysis effectiveness during treatment.

(Logo: )

Adimea, developed by B. Braun and already in use in Europe, is designed for use with B. Braun's Dialog+ Hemodialysis System, provides healthcare professionals with the information they need to give patients the optimal dialysis dose (Kt/V).

U.S. FDA-cleared, the Adimea process uses spectroscopy principles to measure dialysis efficiency by determining the reduction in the molar concentration of urinary excreted substances in the spent dialysate by transmitting an ultraviolet (UV) light source through the dialysate. The highly reliable and precise instrument allows the online determination and continual monitoring of current Kt/V values throughout the patient's entire treatment.  

"Adimea is a very important advancement in renal therapies," said Samuel Amory, Vice President, Renal Therapies Division for B. Braun Medical Inc. "It helps healthcare professionals give their patients an optimal dialysis dose and allows them to adjust treatment parameters for the benefit of patients even during treatment."  

Easy to use and efficient, Adimea requires the entry of only one patient parameter – the patient's weight before dialysis. It saves time by eliminating the determination and entry of the urea volume (V), which enables healthcare professionals to focus more attention on patient care.

For more information or to order Adimea, call 800-848-2066.

About B. Braun

B. Braun is a leading manufacturer of infusion therapy and pain management products with an environmentally-friendly focus. Guided by the company's "Sharing Expertise®" philosophy, B. Braun addresses the critical issues of infection prevention, medication safety and environmental responsibility by promoting best practices that help clinicians reduce medication errors, prevent healthcare-acquired infections (HAIs) and achieve sustainability objectives.

Consistently recognized by Frost & Sullivan and KLAS for its medical technology and support services, B. Braun employees share their knowledge with colleagues and customers to improve working processes in hospitals and medical practices and to enhance the safety of patients and healthcare professionals. For more information, call 800-227-2862, e-mail us at or visit B. Braun at

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. B. Braun Medical Inc. to Demonstrate Infusion Systems Technologies at HIMSS 2009 Interoperability Showcase
2. B. Braun Awarded Contract With HealthTrust Purchasing Group to Provide Pain Management Solutions
3. B. Braun and Amerinet Sign to Expand Infusion Therapy Offerings
4. MEDRAD and B. Braun Melsungen AG Collaborate to Promote Breakthrough Medical Treatment for Cardiovascular Disease
5. B. Braun Introduces WHIN(R) Safe Huber Needle
6. B. Braun Infusion Systems Complete Interoperability Test for HIMSS10 Interoperability Showcase
7. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
10. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
11. EntreMed Shows Increased Survival With MKC-1 in Preclinical Renal Cell Cancer Model
Post Your Comments:
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
Breaking Medicine News(10 mins):